• Iksuda Therapeutics will present preliminary Phase 1 results for IKS014 in HER2-positive solid tumors at the San Antonio Breast Cancer Symposium, December 9, 2026.
• The treatment showed promising antitumor activity, including in heavily pretreated breast cancer patients who previously received Enhertu.
• Safety findings indicated manageable side effects, with no treatment-related serious adverse events or fatal events reported.
• Enrollment continues in expansion cohorts, including breast cancer patients previously treated with Enhertu; the presentation will include updated results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.